# OnCo record camrelizumab-rivoceranib (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/camrelizumab-rivoceranib/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "camrelizumab-rivoceranib" ;
  schema:name "Camrelizumab + rivoceranib"@en ;
  schema:description "A Chinese immunotherapy-plus-anti-angiogenic pill combination that clearly beat sorafenib in liver cancer, yet remains unapproved in the US after three manufacturing-related rejections."@en ;
  schema:url <https://onco.cc/drugs/camrelizumab-rivoceranib/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT03764293> ;
  onco:status "approved" ;
  onco:modality "PD-1 antibody + oral VEGFR2 inhibitor" ;
  onco:approval "China 2023: First-line unresectable HCC" ;
  onco:cancers <https://onco.cc/cancers/hcc/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/antiangiogenic/> ;
  onco:targets <https://onco.cc/targets/pd1/>, <https://onco.cc/targets/vegf/> ;
  onco:companies <https://onco.cc/companies/hengrui/>, <https://onco.cc/companies/elevar-therapeutics/> ;
  onco:trials <https://onco.cc/trials/cares-310/> .